Going gangbusters: The top 20 biotech platform deals by upfront cash
Fortunately, right at the time Regeneron and Alnylam were getting ready to break the news about their billion-dollar partnership, Chris Dokomajilar at DealForma was working up a top-20 list of platform deals from the last decade.
With $800 million for the upfront and equity, the new deal lands right at the number 2 spot for the industry, highlighting just how unusual this pact is for such an early-stage alliance. It’s also Regeneron’s first big turn as the buyer.
Drug developers have been moving upstream more and more, and along wth a burst of M&A we’re also seeing the early, early deals going gangbusters, as Dokomajilar notes in his assessment of the current trends:
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.